Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03955042 · ClinicalTrials.gov registry record · Phase 1
Pemetrexed for the Treatment of Chordoma
A Phase 1 study, sponsored by Saint John's Cancer Institute.
- Completed
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
NCT03955042 is a Phase 1 study that has completed, run by Saint John's Cancer Institute. The registered enrollment target is 15 participants.
The verdict
NCT03955042, a Phase 1 study, has completed, sponsored by Saint John's Cancer Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
Study Summary
The purpose of this study is to test the safety and tolerability of pemetrexed administered to people with chordoma. Other purposes of this study are to: * find out side effects (good and bad) of pemetrexed; * learn more about how pemetrexed might affect the growth of cancer cells; * evaluate tumor characteristics by collecting tumor tissue samples if available; * look at biomarkers (biochemical features that can be used to measure the progress of disease or the effects of a drug) in blood and cerebrospinal fluid if available.
Interventions
- DRUG Pemetrexed
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2019-09-06 |
| Est. Completion | 2023-01-18 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03955042
The ClinicalTrials.gov registry entry for NCT03955042 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Saint John's Cancer Institute, which has 19 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Pemetrexed is the first listed.
NCT03955042 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03955042 about?
NCT03955042 is a clinical study titled "Pemetrexed for the Treatment of Chordoma". The purpose of this study is to test the safety and tolerability of pemetrexed administered to people with chordoma. Other purposes of this study are to: * find out side effects (good and bad) of pemetrexed; * learn more about how pemetrexed might affect the growth of cancer cells; * evaluate tumor...
What is the current status of trial NCT03955042?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2019-09-06. Estimated completion is 2023-01-18.
What interventions are being tested in trial NCT03955042?
The interventions under investigation include: Pemetrexed (DRUG).
Who is sponsoring clinical trial NCT03955042?
This trial is sponsored by Saint John's Cancer Institute, which has 19 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.